[May 09, 2018]

Myomo Reports First Quarter 2018 Results

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the first quarter ended March 31, 2018.

Recent Highlights and Accomplishments:

• Total revenue in the first quarter 2018 was $313,000, an increase of 45%, versus the comparable period of 2017. Product revenue of $309,000, increased 56% versus the comparable period of 2017.
• Increased field sales team by over 100%, and also increased marketing efforts, resulting in a growing number of patient cases in reimbursement claims processing.
• Continued to expand the number of MyoPro Centers of Excellence at Orthotics & Prosthetics (O&P) organizations. Myomo currently has 46 U.S. locations offering the MyoPro line of powered orthosis following 13 new locations added during the first quarter of 2018.
• Working with Ottobock, we have now fit the first patients in Germany and Canada.
• Received $3.6 million from the exercise of approximately 1.2 million warrants at an exercise price of $2.95 per share.
• Cash on hand increased during the quarter to $14.1 million.

Paul R. Gudonis, Chairman & CEO of Myomo, stated: "Early in the year, with the growth capital raised in December 2017, we added resources to scale up operations, including new hires, establishing additional O&P partnerships and launching new marketing campaigns. With a growing number of patients and O&P providers interested in the product, we project to deliver MyoPro to an increasing number of users and continue to expect 2018 revenue growth to exceed reported year ago levels."

First Quarter 2018 Results

Total revenue was $313,000 for the three months ended March 31, 2018; an increase of $97,000, or 45%, as compared to the three months ended March 31, 2017. During the three months ended March 31, 2018, product revenue increased $111,000, or 56%, versus the comparable period of 2017.

Gross margin was 65% for the quarter ended March 31, 2018, as compared to 64% for the three months ended March 31, 2017.

Research and development expenses were $372,000, an increase of $15,000, or 4%, during the three months ended March 31, 2018, as compared to the three months ended March 31, 2017. The increase was primarily due to increased personnel costs.

Selling, general and administrative costs of $2,236,000 increased $1,091,000, or 95%, during the three months ended March 31, 2018, as compared to the same period on 2017. The increase was primarily due to increases in personnel costs of $595,000, which includes $310,000 for additional sales and administrative staff; and $285,000 in share-based compensation expense. Other administrative cost increases include professional fees, rent, insurance, and office expenses of $268,000.

During the three months ended March 31, 2018, the Company generated interest income of $42,000, as compared to interest expense of $141,000 in the same period of 2017. We did not incur interest expense during the three months ended March 31, 2018 due the payoff of our outstanding debt and our convertible promissory notes being converted into common stock upon the closing of our IPO on June 9, 2017.

The Company's net loss for the quarter ended March 31, 2018 amounted to $2,345,000, compared with a net loss of $1,556,000 for the corresponding 2017 period due to the factors described above. Net loss available to common stockholders for the quarter ended March 31, 2018 was $2,345,000 or ($0.20) per share, compared with a net loss available to common stockholders of $1,745,000, or ($1.55) per share, for the corresponding year ago period.

Adjusted EBITDA¹ for the quarter ended March 31, 2018 was a loss of $2,052,000, compared with a loss of $1,341,000 for the corresponding 2017 period. A reconciliation of GAAP to this non-GAAP financial measure has been provided in the financial statement tables included in this press release. An explanation of this measure is also included below under the heading "Non-GAAP Financial Measures."

Cash on hand at March 31, 2018 was $14,116,000, compared to $12,959,000 at December 31, 2017. The increase in cash was primarily due to $3,550,000 of proceeds received for the exercise of warrants during the quarter. This was partially offset by cash used in operating and investing activities of $2,265,000 and $65,000, respectively.

Conference Call and Webcast Information
Myomo will hold a conference call today, May 9, 2018 at 4:30 p.m. EDT. To access the conference call, please dial 1-877-270-2148 from the U.S. or 1-412-902-6510 internationally. Please instruct to be joined into Myomo's earnings conference call.

A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until May 23, 2018; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10119821.

(Tables follow)
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

Forward Looking Statements
This press release contains forward-looking statements regarding the Company's future business expectations, including the scale-up of commercial operations, projected users of MyoPro, the expansion of our MyoPro line to Canada, and the therapeutic potential of our products, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• our sales and commercialization efforts;
• our ability to achieve reimbursement from third-party payers for our products;
• our dependence upon external sources for the financing of our operations;
• our ability to effectively execute our business plan; and
• our expectations as to our clinical research program and clinical results.

More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Non-GAAP Financial Measures
Myomo has provided in this release of financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes that the use of this non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Myomo's industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for the impact of the write off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation, the impact of the fair value revaluation of our derivative liabilities and the loss on early extinguishment of debt. Non-GAAP financial measures that Myomo uses may differ from measures that other companies may use. This non-GAAP financial measure disclosed by Myomo is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

¹ Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted the impact of the write-off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation, the impact of the fair value revaluation of our derivative liabilities and the loss on early extinguishment of debt.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180509006257/en/

[ Back To TMCnet.com's Homepage ]